Malcolm Barratt-Johnson

Chief Tech/Sci/R&D Officer at ALBERT LABS INTERNATIONAL CORP.

Net worth: - $ as of 31/03/2024

61 year

Health Technology

Profile

Malcolm Barratt-Johnson has held positions as a Non-Executive Director at NovaBiotics Ltd.
since 2020 and as Chief Medical Officer at Albert Labs International Corp.
He has no middle name.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
ALBERT LABS INTERNATIONAL CORP. -.--%	21/10/2022	0 ( -.--% )	- $	31/03/2024

Malcolm Barratt-Johnson active positions

Companies	Position	Start
ALBERT LABS INTERNATIONAL CORP.	Chief Tech/Sci/R&D Officer	-
NovaBiotics Ltd. NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.	Director/Board Member	01/10/2020

All active positions of Malcolm Barratt-Johnson

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Malcolm Barratt-Johnson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ALBERT LABS INTERNATIONAL CORP.	Health Technology

Private companies	1
NovaBiotics Ltd. NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.	Health Technology